An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumours

Johann de Bono, Elena Cojocaru, Ruth Plummer‡, Tomasz Kurowski‡, Karen Clegg‡, Fay Ashby‡, Neil Pegg‡, Will West‡, Nigel Brooks‡
Institute of Cancer Research, Royal Marsden NHS Foundation Trust, UK, London, UK; *Newcastle Hospitals NHS Foundation Trust, UK,
‡CellCentric Ltd, Cambridge, UK (email contact: nigel.brooks@cellcentric.com)

Abstract: TPS5089

**Background**

- CCS1477 is a potent, selective and orally bioavailable inhibitor of the bromodomain of p300 and CBP
- CCS1477 inhibits the expression and function of AR-FL, AR-SV and c-Myc
- CCS1477 monotherapy causes complete tumour stasis in a 22Rv1 xenograft model of CRPC, with continued tumour growth block following drug withdrawal

**Study Design**

**Part A: Monotherapy CCS1477 Dose escalation mCRPC**

- Single patient cohorts until related CTCAE Grade 2 toxicity
- Cohorts of 3-6 patients until MTD/RP2D
- Different dose schedules may be evaluated if required

**Part B: Monotherapy CCS1477 Dose expansion mCRPC**

- CCS1477 RP2D-M dose and schedule from Part A
- 25 patients

**Part C: Combination CCS1477/ abiraterone Dose Finding mCRPC**

- CCS1477 in combination with abiraterone
- Starting dose will be MTD/RP2D-M from Part A
- Different dose/schedules may be evaluated if required

**Part D1: Combination CCS1477/ enzalutamide Dose Finding mCRPC**

- CCS1477 in combination with enzalutamide
- Starting dose will be MTD/RP2D-M from Part A
- Different dose/schedules may be evaluated if required

**Part D2: Combination CCS1477/ enzalutamide Dose Expansion mCRPC**

- CCS1477 RP2D-Cmax in combination with enzalutamide
- 25 patients

**Part E: Monotherapy CCS1477 Dose expansion in patients with a p300/CBP mutation**

- CCS1477 RP2D-M dose and schedule from Part A
- Advanced solid tumours with confirmed p300/CBP mutation
- 25 patients

**Primary objective**

- Investigate the safety and tolerability of CCS1477 as monotherapy and in combination with abiraterone or enzalutamide

**Secondary objectives**

- Obtain a preliminary assessment of the anti-tumour activity of CCS1477 as monotherapy and in combination with abiraterone or enzalutamide in patients with mCRPC by measurement of changes in PSA, CTCs, RECIST and metastatic bone disease status
- Characterise the PK of CCS1477, following a single dose and at steady state after multiple dosing, when given as a single agent or in combination
- Characterise the PK of abiraterone and enzalutamide when dosed in combination with CCS1477
- Obtain a preliminary assessment of the anti-tumour activity of CCS1477 in patients with advanced solid tumours with a confirmed mutation in p300 or CBP

**Patient criteria**

**For patients with mCRPC**

- Previous treatment with abiraterone and/or enzalutamide and a taxane (unless ineligible or refused)
- Evidence of disease progression (PCWG-3 guidelines)
- For parts C&D, patients whose last dose of abiraterone or enzalutamide is >6 months prior to start of study will receive a 4-wk run-in treatment to confirm refractoriness to treatment

**For patients with a solid tumour p300/CBP mutation**

- Histological or cytological confirmation of malignancy that is advanced and not considered to be appropriate for further approved/standard of care treatment
- Advanced solid tumour with a confirmed mutation in p300 or CBP

**Status**

- Cohort 1 and 2 of dose-escalation (rolling 6 design; 3-6 patients/cohort) has completed
- Currently recruiting to Cohort 3